Arterial hypertension and chronic obstructive pulmonary disease: clinical characteristics and treatment efficasy (according to the national register of arterial hypertension)


Cite item

Full Text

Abstract

Arterial hypertension (AH) is one of the major factors, causing high level of population mortality in many countries, including Russia. Natural aging of population in the beginning of 20th century leads to medical and social issues; and frequent comorbidity is one of them. The occurrences of chronic obstructive pulmonary disease (COPD) are rather often among the population, especially among city dwellers and males. AH and COPD are frequent comorbid conditions; combination of these diseases contributes to high level of disability and poor prognosis. The objective of the research is studying of demographic and clinical profile as well as treatment effectiveness of patients with AH and COPD based on National Register of Arterial Hypertension. Methods and materials. Among the analyzed selection, consisted of 32 571 patients with AH, who were followed up in the primary medical care, at the average age of 64±7 years old (there were 64% women of them), 5.4% patients with AH had COPD. The analysis of cardiovascular and cerebrovascular diseases frequency as well as treatment effectiveness was made. Results. According to National Register of Arterial Hypertension, cardiovascular [coronary heart disease, Q myocardial infarction, chronic heart failure (CHF), peripheral artery atherosclerosis] and cerebrovascular (stroke/transitory ischemic attack) diseases are accurately more often diagnosed at patients with AH and COPD. Conclusion. Male sex and age are the strongest independent factor, contributing into the risk of development of cardiovascular diseases at these patients. COPD considerably increases the risk of CHF development. The conducted analysis has shown that treatment, prescribed to patients with AH and COPD meets modern recommendations.

About the authors

I E Chazova

National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation

акад. РАН, д.м.н., проф., директор, руководитель отд. гипертонии; ORCID: 0000-0002-9822-4357 Moscow, Russia

N V Lazareva

National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation

Email: n.lazareva@list.ru
к.м.н., с.н.с. лаб. мониторинга программ по снижению смертности от сердечно-сосудистых заболеваний Moscow, Russia

E V Oshchepkova

National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation

д.м.н., проф., руководитель лаб. мониторинга программ по снижению смертности от сердечно-сосудистых заболеваний Moscow, Russia

References

  1. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно - сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;10:4-12 https://doi.org/10.26442/terarkh20189098-14
  2. Чазова И.Е., Ощепкова Е.В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002-2012 гг. Вестник Российской академии медицинских наук. 2013;2:4-11
  3. Heart disease and Stroke statistics - 2016 update: a report from the American Heart Association. Circulation. 2016;133.
  4. Wolf-Maier K, Cooper R.S, Banegas J.R, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA. 2003;289:2363-9. doi: 10.1001/jama.289.18.2363
  5. Клинические рекомендации «Диагностика и лечение артериальной гипертонии». Рабочая группа по подготовке текста: Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Кардиологический вестник. 2015;1:5-30
  6. ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31(7):1281-357. doi: 10.1097/01.hjh. 0000431740.32696.cc.
  7. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, Chan K.Y, Sheikh A, Rudan I. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta - analysis. J Glob Health. 2015;5(2):020415. doi: 10.7189/ jogh.05-020415.
  8. Haeusler K.G, Herm J, Konieczny M. Impact of chronic inflammatory airway disease on stroke severity and longterm survival after ischemic stroke - a retrospective analysis. BMC Neurol. 2015;15:164. doi: 10.1186/s12883-015-0414-1
  9. Hardie J.A, Vollmer W.M, Buist A.S, Bakke P, Morkve O. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years. Respir Med. 2005;99:186-95. https://doi.org/10.1016/ j.rmed.2004.06.006
  10. Halbert R.J, Natoli J.L, Gano A, Badamgarav E, Buist A.S, Mannino D.M. Global burden of COPD: systematic review and meta - analysis. Eur Respir J. 2006;28:523-32. doi: 10.1183/09031936.06.00124605
  11. Zeng L.H, Hu Y.X, Liu L, Zhang M, Cui H. Impact of beta2-agonists, betablockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging. 2013;8:1157-65. doi: 10.2147/CIA.S49644. Epub 2013 Sep 10
  12. Задионченко В.С., Волкова Н.В., Копалова С.М. Системная и легочная гипертония при хронических неспецифических заболеваниях легких. Русский медицинский журнал. 1996;4(12):28-37
  13. Задионченко В.С., Адашева Т.В., Шилова Е.В. и др. Клинико - функциональные особенности артериальной гипертонии у больных хроническими обструктивными болезнями легких. Русский медицинский журнал. 2003;11(9):535-8
  14. Кубышкин В.Ф., Солдатченко С.С., Коновалов В.И. Особенности течения хронических обструктивных заболеваний легких в сочетании с системной артериальной гипертензией. Терапевтический архив. 1985;57(2):114-6
  15. Dart R.A, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
  16. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794-800.
  17. Rabahi M.F, Pereira S.A, Silva Júnior J.L, de Rezende A.P, Castro da Costa A, de Sousa Corrêa K, et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10:1525-9. doi: 10.2147/COPD.S85588
  18. Rabe K.F, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-55. doi: 10.1164/rccm.200703-456SO
  19. Vogelmeier C.F, Criner G.J, Martinez F.J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-82. doi: 10.1164/rccm.201701-0218PP
  20. Nicola Di Daniele. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD. J Pulmonary Pharmacology & Therapeutics. 2015;35:1-7.
  21. Goncalves J, Sanchez R, et al. Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study). J Clin Investig Arteriosclerosis. 2017;29(4):149-56.
  22. Чазова И.Е. Артериальная гипертония и хроническая обструктивная болезнь легких. Consilium medicum. 2006;8(5)
  23. Чазова И.Е., Чучалин А.Г., Зыков К.А., Ратова Л.Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Editorial Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013;1:5-34
  24. Ощепкова Е.В., Лазарева Н.В., Чазова И.Е. Оценка качества обследования больных артериальной гипертонией в первичном звене здравоохранения (по данным российского Регистра артериальной гипертонии). Системные гипертензии. 2017;14(2):29-34. https://doi.org/10.26442/
  25. Finkelstein J, Cha E, Scharf S.M. Chronic obstructive pulmonarydisease as an independent risk factor for cardiovascular morbidity. Int J Chronic Obstr Pulmon Dis. 2009;4:337-49.
  26. Feary J.R, Rodrigues L.C, Smith C.J, Hubbard R.B, Gibson J.E. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956-62. doi: 10.1136/thx.2009.128082
  27. de Lucas-Ramos P, Izquierdo-Alonso J.L, Rodriguez-Gonzalez Moro J.M, Frances J.F, Lozano P.V, Bellón-Cano J.M, CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case - control study (CONSISTE study). Int J Chronic Obstr Pulmon Dis. 2012;7:679-86. doi: 10.2147/COPD.S36222
  28. Dal Negro R.W, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10:24. doi: 10.1186/s40248-015-0023-2
  29. Lunde H, Hedner T, Samuelsson O et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994;308:18-21.
  30. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double - blind study comparing the incidenceof cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-7.
  31. Barnes P.J. Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol. 1985;20(Suppl. 2):289-98.
  32. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Claus F. Vogelmeier, Gerard J. Criner Arch Bronconeumol. 2017;53(3):128-49. www.archbronconeumol.org. doi: 10.1016/j.arbres.2017.02.001
  33. Sato N, Kajimoto K, et al. Acute demopensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: Rationale, desing, and preliminary data. Am Heart J. 2010;159:949-56. doi: 10.1016/j.ahj.2010.03.019
  34. Adams Jr K.F, Fonarow C.C, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16. doi: 10.1016/j.ahj.2004.08.005
  35. Abraham W.T, Fonarow G.C, et al. Predictor of in - hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-56.
  36. Jonsson Asa, Edner Magnus, Alehagen Urban, et al. Heart failure register: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail. 2010;12:25-31.
  37. Ruiz-Laiglesia F.J, Sanchez-Marteles M, Perez-Calvo J.I, et al. Comorbidity in heart failure. Results of the Spanish RICA Register. QJM. 2014;107:989-94.
  38. Lauthavorn P, Hengrussamee K. Thai acute decompensated heart failure registry (Thai ADHERE). J CVD Prevention and Control. 2010;5:89-95. doi: 10.1016/j.cvdpc.2010.06.001
  39. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta - blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;19:CD003566. doi: 10.1002/14651858.CD003566.pub2
  40. Mario Malerba, Paolo Montuschi, et al. Role of beta - blockers in patients with COPD: current perspective. Drug Discovery Today Volume. 2015;20(1):129-35.
  41. Dart R, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
  42. ONTARGET Investigators, Yusuf S, Teo K, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
  43. Heart disease and Stroke statistics - 2016 update: a report from the American Heart Association. Circulation. 2016;133.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies